Atherosclerosis Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The atherosclerosis drugs market size was valued at USD 34.39 billion in 2025 and estimated to grow from USD 35.43 billion in 2026 to reach USD 41.08 billion by 2031, at a CAGR of 3.01% during the forecast period (2026-2031). This report is Segmented by Drug Class (Statins, PCSK9 Inhibitors, Bempedoic-Acid & ACL Inhibitors, Antiplatelet Agents, Omega-3 Fatty-Acid Derivatives, RNA-Based Therapies, Others), Distribution Channel (Retail, Hospital, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Atherosclerosis Drugs Market Trends and Insights

Rising Prevalence of CVD & Aging Population

Global life expectancy gains, urban sedentary lifestyles, and metabolic comorbidities combine to keep ASCVD the top cause of mortality worldwide. Low- and middle-income regions now account for 80% of cardiovascular deaths, creating structurally high unmet need for lipid-modifying therapies that are both affordable and scalable. The dual burden of diabetes and obesity escalates plaque formation and shifts onset to younger adults, extending lifetime drug exposure. Prevalence trends underpin sustained unit growth across the atherosclerosis drugs market, even as therapeutic intensity increases in elderly cohorts with polypharmacy constraints. Long-acting injectables and six-monthly siRNA regimens address adherence gaps common in chronic disease management, while fixed-dose oral combinations simplify treatment for primary-care settings in resource-constrained geographies.

Guideline-Driven Uptake of Statins & PCSK9 Inhibitors

The 2025 ACC/AHA guideline mandates high-intensity statins for acute coronary syndrome and advocates non-statin add-ons once LDL-C remains ≥70 mg/dL despite therapy. Parallel European and International Lipid Expert Panel positions promote earlier dual-therapy initiation, broadening the eligible pool for PCSK9 inhibitors beyond historic statin-intolerant niches. Real-world registries demonstrate cardiovascular event reduction proportional to achieved LDL-C levels, reinforcing guideline influence on prescribing as payers reward goal attainment. Harmonized targets build a common language across regions, yet implementation still hinges on local reimbursement rules, physician familiarity, and health-technology-assessment outcomes.

Generic Erosion Post-Patent Expiry of Statins

Loss of exclusivity for atorvastatin and rosuvastatin demonstrated rapid price declines of more than 80% within 18 months of generic launch. Forthcoming expiries rivaroxaban in May 2025 and sacubitril/valsartan mid-2025 extend contractionary effects, squeezing brand revenues and shifting payer formularies toward lowest-cost options. Manufacturers pursue lifecycle-management tactics such as fixed-dose combinations and novel delivery forms in an effort to delay share attrition, yet these pivots rarely offset the steep volume shift to multisource products. While generics preserve therapy accessibility, they also compress overall atherosclerosis drugs market value in regions where statins dominate total prescriptions.

Other drivers and restraints analyzed in the detailed report include:

• Higher Healthcare Spending & Drug Accessibility
• Awareness Campaigns & Lipid-Screening Programs
• Poor Long-Term Adherence Due to Side-Effects

Segment Analysis

Statins anchored 58.74% of the atherosclerosis drugs market share in 2025, owing to well-established efficacy, low cost, and broad guideline endorsement. The volume uplift they provide keeps the atherosclerosis drugs market size substantial despite headline price compression. PCSK9 inhibitors are forecast to deliver a 5.18% CAGR through 2031 on expanded indications for very high-risk patients and on payer acceptance of outcome-based contracting. Sales acceleration is also aided by maturing real-world evidence confirming 50-60% incremental LDL-C reductions on top of statins, translating into fewer cardiac events. Oral ATP-citrate lyase (ACL) inhibitors such as bempedoic acid attract statin-intolerant populations that previously lacked convenient alternatives, nudging prescription volumes higher in primary-care settings.

Pipeline momentum intensifies around RNA-based modalities: inclisiran solidifies a semi-annual dosing archetype, while ASOs targeting lipoprotein(a) line up for first global submissions in 2026. These additions enlarge the high-value biologic cohort and diversify the mechanism risk, offsetting some revenue lost to statin generics. Meanwhile, anti-inflammatory therapies like low-dose colchicine and monoclonal antibodies against IL-1β offer adjunctive pathways for risk reduction, hinting at multi-modal regimens that will expand the addressable pool. Collectively, innovation lengthens the premium tail of the atherosclerosis drugs market even as unit growth in legacy categories flattens.

Complete Report Scope:

• By Drug Class
  • Statins
  • PCSK9 Inhibitors
  • Bempedoic-acid & ACL inhibitors
  • Antiplatelet Agents
  • Omega-3 Fatty-acid Derivatives
  • RNA-based Therapies (ASO & siRNA)
  • Others
• By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 38.12% of 2025 sales, sustained by guideline adoption, payer coverage for premium biologics, and a deep clinical-trial ecosystem that keeps innovation cycles short. The region benefits from FDA breakthrough designations that bring first-in-class treatments like CRISPR-based VERVE-102 to market ahead of other jurisdictions. Nevertheless, Medicare price negotiations and state-level importation initiatives heighten price elasticity, prompting strategic contracting and outcome-based deals. Digital adoption is high: remote lipid monitoring, prescription apps, and AI adherence coaching reinforce the value of combination regimens and help protect premium segments within the atherosclerosis drugs market.

Asia-Pacific is the fastest-growing region, with a 6.07% CAGR to 2031. Universal health coverage expansion, urbanization, and dietary westernization drive ASCVD prevalence, while local biosimilar PCSK9 launches improve affordability. India amplifies generic exports and internal demand, leveraging its PLI scheme to scale low-cost supply. Japan’s regulatory reforms incentivize multinational trial investment, though its rapidly aging population strains insurance budgets. Collectively, regional heterogeneity requires nuanced pricing and localization strategies but presents the single largest volume upside for the atherosclerosis drugs market.

Europe registers steady expansion supported by harmonized EMA guidelines and widespread public-health screening programs. Health-technology-assessment bodies impose stringent cost-effectiveness thresholds, fostering uptake of fixed-dose combinations and generics where outcome parity is demonstrated. Eastern European markets gain share as infrastructure improves, offering a growth relay as Western budgets tighten. Middle East & Africa and South America remain nascent but attractive in the long term. Cardiovascular disease awareness is rising, and private insurance penetration is widening in Gulf Cooperation Council states and Brazil, yet public-sector budgets lag, limiting the immediate uptake of high-cost biologics. Nonetheless, partnership models with government import agencies and local distributors lay the groundwork for future expansion of the atherosclerosis drugs market.

List of Companies Covered in this Report:

• AstraZeneca
• Amgen
• Merck
• Regeneron Pharmaceuticals
• Novartis
• Pfizer
• Sanofi
• GlaxoSmithKline
• Bayer
• Viatris
• Eli Lilly and Company
• Boehringer Ingelheim
• Amarin Corporation
• Esperion Therapeutics
• Ionis Pharmaceuticals
• Alnylam Pharmaceuticals
• CSL Behring
• Daiichi Sankyo
• Silence Therapeutics
• Roche

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support